Recursion Pharmaceuticals, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
| Przychód (średnia) |
70.75 |
68.77 |
104.50 |
211.84 |
194.30 |
| Przychód Δ r/r |
0.00% |
-2.80% |
51.96% |
102.72% |
-8.28% |
| Przychód (min) |
63.61 |
32.74 |
45.00 |
211.84 |
97.80 |
| Przychód (max) |
85.45 |
109.38 |
208.40 |
211.84 |
329.44 |
| EBITDA (średnia) |
-70.75 |
-68.77 |
-104.50 |
-211.84 |
-194.30 |
| EBIT (średnia) |
-70.75 |
-68.77 |
-104.50 |
-211.84 |
-194.30 |
| EBIT % |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
| Zysk netto (średni) |
-421.94 |
-400.67 |
-316.71 |
-164.40 |
-260.50 |
| Zysk netto % |
-596.39% |
-582.64% |
-303.06% |
-77.60% |
-134.07% |
| EPS (średnia) |
-1.54 |
-1.46 |
-1.15 |
-0.73 |
-0.95 |
| Liczba analityków (Przychody) |
7 |
6 |
9 |
3 |
1 |
| Liczba analityków (EPS) |
6 |
6 |
7 |
1 |
1 |
| symbol |
RXRX |
RXRX |
RXRX |
RXRX |
RXRX |